ArticleOrphanet journal of rare diseases2026
Clinical application of an Asian Screening Array-based preimplantation genetic testing workflow for various genetic disorders.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundPreimplantation genetic testing for monogenic disorders (PGT-M) represents a critical clinical strategy for preventing the transmission of hereditary diseases from carriers to offspring, with its diagnostic efficacy heavily dependent on the accuracy and coverage of detection platforms. Genome-wide SNP array such as the Asian Screening Array (ASA), has demonstrated favorable performance in haplotype analysis for PGT-M. Here, we systematically evaluated the efficiency of the Asian Screening Array-based PGT workflow in PGT application for different genetic disorders.
methodsWe conducted a retrospective analysis by reviewing 377 pedigrees underwent PGT-M preclinical work-up and 367 PGT-M clinical cycles (1677 embryos in total) based on the Asian Screening Array. We established detection strategies combining ASA haplotyping analysis and individualized direct mutation detection based on different genetic patterns. Long-read sequencing or single-sperm haplotyping strategy was applied for families with de novo pathogenic variants or lacking family member samples. Individualized direct mutation detection methods such as Gap-PCR, RP-PCR, PCR-RFLP were adopted for different cases.
resultsResults indicated the clinical validity of our ASA-based PGT workflow, integrating linkage analysis, direct mutation detection, and chromosomal CNV screening. The number of SNPs available for linkage analysis in the upstream and downstream regions of target genes/regions is sufficient for most of the cases. Individualized direct mutation detection methods for different cases also validated the ASA haplotyping results. In haplotype analysis, the method based on long-read sequencing is more effective than single-sperm haplotyping strategy. Detailed haplotyping strategy for families with microdeletions and tandem duplications was established based on ASA. A total of 636 embryos were ultimately deemed suitable for transfer after undergoing linkage analysis and CNV detection.
conclusionThis study validated the feasibility and superiority of ASA-based approach in PGT, also provided a standardized and reliable technical solution for the clinical prevention of different genetic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.